Mineralys Therapeutics, Inc. financial data

Symbol
MLYS on Nasdaq
Industry
Pharmaceutical Preparations
Location
150 N. Radnor Chester Road, Suite F200, Radnor, PA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.65K %
Return On Equity -42.6 % -27.6%
Return On Assets -40.1 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49.7M shares +21.7%
Common Stock, Shares, Outstanding 49.7M shares +21.7%
Entity Public Float 240M USD
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 49.4M shares +24.2%
Weighted Average Number of Shares Outstanding, Diluted 49.4M shares +24.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 116M USD +205%
General and Administrative Expense 18.3M USD +82.1%
Operating Income (Loss) -135M USD -180%
Nonoperating Income (Expense) 14.8M USD +95.2%
Net Income (Loss) Attributable to Parent -120M USD -195%
Earnings Per Share, Basic -2.7 USD/shares +29.9%
Earnings Per Share, Diluted -2.7 USD/shares +29.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 67.9M USD -32.9%
Assets, Current 318M USD +18%
Property, Plant and Equipment, Net 42K USD
Other Assets, Noncurrent 449K USD +780%
Assets 318M USD +9.37%
Accounts Payable, Current 1.71M USD -22.3%
Accrued Liabilities, Current 26.7M USD +565%
Liabilities, Current 28.4M USD +358%
Retained Earnings (Accumulated Deficit) -197M USD -154%
Stockholders' Equity Attributable to Parent 290M USD +1.78%
Liabilities and Equity 318M USD +9.37%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -19.1M USD -49.8%
Net Cash Provided by (Used in) Financing Activities 116M USD -42.9%
Net Cash Provided by (Used in) Investing Activities -56M USD +60.1%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 49.7M shares +21.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 41.1M USD -18.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 67.9M USD -32.9%
Deferred Tax Assets, Valuation Allowance 31.5M USD +144%
Deferred Tax Assets, Gross 31.5M USD +144%
Deferred Tax Assets, Operating Loss Carryforwards 7.89M USD +37.5%
Unrecognized Tax Benefits 1.08M USD +312%
Additional Paid in Capital 487M USD +34.4%
Depreciation, Depletion and Amortization 8K USD
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 8.1M USD +233%